Legend Biotech Corporation (LEGN)

NASDAQ: LEGN · IEX Real-Time Price · USD
67.58
+0.58 (0.87%)
Feb 27, 2024, 9:42 AM EST - Market open
0.87%
Market Cap 12.37B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 182.29M
EPS (ttm) -2.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,927
Open 68.00
Previous Close 67.00
Day's Range 67.48 - 68.16
52-Week Range 42.91 - 77.32
Beta -0.02
Analysts Buy
Price Target 83.75 (+23.93%)
Earnings Date Mar 11, 2024

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 5, 2020
Employees 1,390
Stock Exchange NASDAQ
Ticker Symbol LEGN
Full Company Profile

Financial Performance

In 2022, Legend Biotech's revenue was $117.01 million, an increase of 70.00% compared to the previous year's $68.83 million. Losses were -$446.35 million, 10.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is $83.75, which is an increase of 23.93% from the latest price.

Price Target
$83.75
(23.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the Committee for Medicinal Products for Human Use (CHMP) ...

4 days ago - Business Wire

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life...

14 days ago - Business Wire

GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector

NANJING, China , Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, w...

7 weeks ago - PRNewsWire

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life...

7 weeks ago - Business Wire

Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life...

2 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such investors are advis...

2 months ago - PRNewsWire

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life...

2 months ago - Business Wire

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced third-quarter 2023 financial results.

3 months ago - Business Wire

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

3 months ago - Business Wire

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

4 months ago - Business Wire

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces presentations to take place at the 65th American Society of Hematology Annual Meeting.

4 months ago - Business Wire

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech reported its unaudited financial results for the three and six months ended June 30, 2023.

7 months ago - Business Wire

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech will host a call to discuss second-quarter 2023 earnings on August 15, 2023 at 8:00am ET.

7 months ago - Business Wire

Legend Biotech shares gain on multiple-myeloma drug sales

Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, -0.20%, generate...

7 months ago - Market Watch

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA).

9 months ago - Business Wire

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Results from CARTITUDE-4 showed that cilta-cel reduced the risk of disease progression or death by 74% compared to SOC.

9 months ago - Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

9 months ago - Business Wire

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that a Type II variation application was submitted to EMA for CARVYKTI® based on data from the CARTITUDE-4 study.

9 months ago - Business Wire

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

10 months ago - Business Wire

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces that new and updated data from the CARTITUDE program will be presented at the 2023 ASCO and EHA annual meetings.

10 months ago - Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

10 months ago - Business Wire

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat lif...

10 months ago - Business Wire

Why Legend Biotech Stock Is Having Its Best Month Yet

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.

11 months ago - MarketBeat

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Where is the current bull market? All indications would be that it's in biotech!

11 months ago - Benzinga

Legend Biotech Announces Appointment of Chief Medical Officer

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel thera...

11 months ago - Business Wire